行情

QURE

QURE

Uniqure
NASDAQ

实时行情|Nasdaq Last Sale

51.52
-2.50
-4.63%
盘后: 52.87 +1.35 +2.62% 16:11 04/09 EDT
开盘
54.84
昨收
54.02
最高
55.93
最低
49.99
成交量
38.06万
成交额
--
52周最高
82.49
52周最低
36.20
市值
22.80亿
市盈率(TTM)
-16.6510
分时
5日
1月
3月
1年
5年

分析师评级

18位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测QURE价格均价为85.81,最高价位105.00,最低价为73.00。

EPS

QURE 新闻

更多
  • uniQure (QURE) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 2天前
  • FDA OKs new hemophilia treatment
  • Seeking Alpha - Article · 04/01 17:51
  • uniQure to Participate in Multiple Upcoming Investor Conferences in April
  • GlobeNewswire · 03/30 12:00
  • Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE)
  • Insider Monkey · 03/29 01:10

所属板块

生物技术和医学研究
+1.63%
制药与医学研究
+0.82%

热门股票

代码
价格
涨跌幅

QURE 简况

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
展开

微牛提供Uniqure NV(NASDAQ-QURE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的QURE股票新闻,以帮助您做出投资决策。